Cardiac drug sales: Who’s on top & who’s slipping

Candace Stuart | | Cardiovascular Business | Economics

AstraZeneca led the pack of pharmaceutical companies for revenue from cardiovascular drugs in 2014, according to a PMLive analysis. But of the top 10 companies, only Bayer and Takeda posted growth in sales that year. Here are figures for the leading companies.

Top 25 pharma companies by cardiovascular sales

Subscribe to Cardiovascular Business News

Candace Stuart, Contributor

Related Content

Heart surgeons now earn more than $1 million per year
Cardiology’s busy year: Compensation, productivity, imaging volumes and TAVR cases all on the rise for heart specialists
What private practices, hospitals and investors should know about the M&A market in cardiology
Siemens Healthineers doubles down on cardiovascular care as it exits general imaging ultrasound business
Policy expert explains why cardiology services in the US are getting more expensive
Rural cardiology practices struggle to fill vacancies

Around the web

Health Exec
An inside look at the changing culture of the FDA
Health Exec
FDA balances faster AI adoption with safety as healthcare technology advances
Radiology Business
Maryland mammography law turns incidental cardiac findings into a new screening opportunity

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News